Virtual

ATTRUBY (Acoramidis) from BridgeBio for the Treatment of Transthyretin Amyloidosis (ATTR-CM) (Co-organized with Stanford SPARK Platform) REGISTER»  

Speakers Daksh Thaper, PhD (J&J) Paul Sorenson, MD, PhD (BC Cancer) Alaa Amash, PhD (Abcelleria) Corinne Ramos, PhD (Aliri Bioanalysis) REGISTER»  

This PBSS workshop will present cutting-edge tools, methods, and case studies for predicting human pharmacokinetics (PK) and dose selection across various modalities, including small molecules, oligonucleotides, and biologics. Topics include machine learning-based PK prediction, cross-industry efforts from the IQ Consortium, and applications to emerging modalities such as siRNAs and PROTACs. The workshop will also cover..

As the field of drug development continues to evolve, the formulation of small synthetic molecules remains a critical component in the journey from discovery to early clinical trials. This workshop aims to deepen participants' understanding of the key strategies and challenges in preclinical and early clinical formulation development. Experts will share their insights on the..

Using different examples of lyocake defects, Biopharma Group's Senior Scientist, Dr. Bhaskar Pandya, will explain how to identify these issues—even when they’re not visible to the naked eye—and share effective strategies for resolving them. The session will cover key techniques such as Freeze Drying Microscopy (FDM) analysis and understanding collapse temperature. REGISTER» Event Host

Join us for an insightful webinar on how biomedical text and data mining—powered by cutting-edge AI technologies like RAG-LLMs, Model Context Protocol, and NLWeb—can transform pharmaceutical R&D. In this session, we will focus on: How structured, enriched, and curated scientific literature in drug discovery through cutting-edge AI technologies can foster innovation Ways to uncover critical..

Register for a free NIH technology webinar to learn about a potential, novel treatment for Triple Negative Breast Cancer (TNBC). William Reinhold and his team at the National Cancer Institute repurposed two separate therapeutic compounds ─ acetalax and bisacodyl (both previously used as laxatives) ─ into novel treatments for TNBC. Attend to learn more about this..

Speakers' Bios Jason Crawford, PhD Executive Vice President, Drug Discovery (Gandeeva Therapeutics) Jason Crawford oversees drug development at Gandeeva Therapeutics by translating structural insights derived from cryo-EM and computational predictions into novel medicines. Jason held roles of increasing scientific responsibility and portfolio oversight at adMare BioInnovations (formerly CDRD), with the most senior role as Venture..